Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026)

Bristol Myers Squibb (CELG-RI) posted quarterly Income from Non-Controlling Interests of $1.0 million for Q1 2026, down 83.33% YoY from $6.0 million in Q1 2025, and up 200.0% sequentially from -$1.0 million in Q4 2025.

Bristol Myers Squibb (CELG-RI) Income from Non-Controlling Interests (2009 - 2026) Analysis & Trends

Bristol Myers Squibb has disclosed Income from Non-Controlling Interests across 18 years of filings, most recently posting $1.0 million for Q1 2026.

  • In Q1 2026, Income from Non-Controlling Interests fell 83.33% year-over-year to $1.0 million; the TTM figure through Mar 2026 stood at -$4.0 million (down 122.22% YoY), while the FY2025 annual figure was $2.0 million, down 86.67% from the prior year.
  • Income from Non-Controlling Interests climbed to $1.0 million in Q1 2026, from -$1.0 million in the prior quarter.
  • Over the last five years, Income from Non-Controlling Interests for CELG-RI reached as high as $8.0 million in Q2 2022 and fell as low as -$6.0 million in Q3 2025.
  • The 5-year median for Income from Non-Controlling Interests is $4.0 million (2023), against an average of $3.1 million.
  • Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests jumped 200.0% — and 2025, when it tumbled 250.0%.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at $3.0 million in 2022, then jumped by 100.0% to $6.0 million in 2023, then sank by 33.33% to $4.0 million in 2024, then plunged by 125.0% to -$1.0 million in 2025, then jumped by 200.0% to $1.0 million in 2026.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered $1.0 million, -$1.0 million, and -$6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn 2.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn 1.00 Mn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -3.00 Mn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn -
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 8.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Bristol Myers Squibb 244.56 Mn -10.21 Bn 8.07 Bn 1.00 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 1.00 Mn
Dec 31, 2025 -1.00 Mn
Sep 30, 2025 -6.00 Mn
Jun 30, 2025 2.00 Mn
Mar 31, 2025 6.00 Mn
Dec 31, 2024 4.00 Mn
Sep 30, 2024 4.00 Mn
Jun 30, 2024 4.00 Mn
Mar 31, 2024 3.00 Mn
Sep 30, 2023 6.00 Mn
Jun 30, 2023 4.00 Mn
Mar 31, 2023 5.00 Mn
Dec 31, 2022 3.00 Mn
Sep 30, 2022 2.00 Mn
Jun 30, 2022 8.00 Mn
Mar 31, 2022 5.00 Mn
Sep 30, 2021 6.00 Mn
Jun 30, 2021 6.00 Mn
Mar 31, 2021 8.00 Mn
Sep 30, 2020 6.00 Mn